Begin Phase 1 clinical testing of ADX-248
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 20 Jun 2024
- Due
- 31 Dec 2024
- Delivered
- by 1 Nov 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 1 clinical testing of ADX-248 is expected to begin in the second half of 2024.”
What we found
Evidence strength A What the grades mean
Phase 1 clinical testing of ADX-248 began in the second half of 2024 as expected; active dosing confirmed by early 2025.
-
A SEC Filing
“ADX-248 Phase 1 dose escalation in healthy subjects ongoing at doses in excess of 100 mg QD” ✓ confirmed on the page
-
B Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
“Phase 1 clinical testing of ADX-248 is expected to begin in the second half of 2024.”
Checked 7 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Begin
- Deliverable
- Phase 1 clinical testing of ADX-248
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-ALDX-003547 · Corrections policy